Received: DecemAccepted: AugPublished: August 12, 2022Ĭopyright: © 2022 Pe et al. PLoS ONE 17(8):Įditor: Dominique Heymann, Universite de Nantes, FRANCE (2022) Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness. These cancer-induced TAMs further enhance tumor cell growth and aggressiveness.Ĭitation: Pe KCS, Saetung R, Yodsurang V, Chaotham C, Suppipat K, Chanvorachote P, et al. In conclusion, TNBC cells induce macrophage polarization with a mixture of M1 and M2 phenotypes. Among these M1-associated genes, CXCL10 and IL1B were revealed to be independent prognostic factors for disease progression. Consistently, TCGA and MTABRIC analyses of human breast cancer revealed upregulation of M1- associated genes in TNBC comparing with non-TNBC. Theses TNBC-induced TAMs exert aggressive behavior of TNBC cells. Distinct from the classical M2 macrophage, TAMs generated from TNBC-conditioned media upregulated both M1- and M2-associated genes, and secreted both the anti-inflammatory cytokine interleukin IL-10 and the proinflammatory cytokine IL-6 and tumor necrosis factor- α. Cytokine-polarized M2 macrophage were used as control. Therefore, this study aimed to evaluate the crosstalk between cancer cells and macrophages in the context of TNBC. Moreover, breast cancer cells can secrete factors that influence TAM polarization. TAMs consist of a heterogeneous population with high plasticity and are associated with tumor aggressiveness and poor prognosis. FDA approves Keytruda® (pembrolizumab) for treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery.Triple-negative breast cancer (TNBC) is characterized by excessive accumulation of tumor-infiltrating immune cells, including tumor-associated macrophages (TAMs). indication for PD-L1-positive, metastatic triple-negative breast cancer.
Triple negative breast cancer prognosis update#
Genentech provides update on Tecentriq U.S. Can we cure stage IV triple-negative breast carcinoma? Another case report of long-term survival (7 years). Case report of long-term survival with metastatic triple-negative breast carcinoma: treatment possibilities for metastatic disease. Triple-negative breast cancer.Ĭhue BM, La Course BD. 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years. Post-recurrence survival in triple negative breast cancer. Morante Z, De la Cruz Ku GA, Enriquez D, et al.
Triple negative breast cancer prognosis free#
Long-term survival outcomes of triple-receptor-negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. A multigene assay determines risk of recurrence in patients with triple-negative breast cancer. Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (≥60) patients. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Favorable long-term outcome in male breast cancer. Triple negative breast cancer - an overview.
0 kommentar(er)
